MiniMed Group, Inc.
22.76USD
-0.5600 (-2.40%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.1▼ | $0.13 | 0 | 1 |
| Next quarter | $0.2▲ | $0.11 | 0 | 0 |
| Current year | $0.68▲ | $0.65 | 0 | 1 |
| Next year | $0.65▼ | $0.73 | 0 | 1 |
Beat in 1 of the last 3
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-07-31 | $0.1 | $0.13 | +0.04 (+37.8%) |
| 2026-04-30 | $-0.22 | $-0.6 | -0.38 (-171.8%) |
| 2026-01-31 | $0.13 | $-0.47 | -0.60 (-461.9%) |
21 ratings from 12 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Morgan Stanley | Maintained | Overweight | $19 $21 | Sep 3, 2026 |
| Citigroup | Maintained | Buy | $23 $26 | Sep 2, 2026 |
| Evercore ISI Group | Maintained | Outperform | $20 $27 | Sep 2, 2026 |
| Wells Fargo | Maintained | Overweight | $22 $26 | Sep 2, 2026 |
| UBS | Maintained | Buy | $25 $28 | Sep 2, 2026 |
| Mizuho | Maintained | Outperform | $21 $26 | Sep 2, 2026 |
| B of A Securities | Maintained | Buy | $24 $28 | Sep 2, 2026 |
| BTIG | Maintained | Buy | $25 $28 | Sep 1, 2026 |
| Wells Fargo | Maintained | Overweight | $26 $22 | Jun 4, 2026 |
| B of A Securities | Maintained | Buy | $27 $20 | May 18, 2026 |
| Benchmark | Initiated | Buy | $20 | May 12, 2026 |
| Barclays | Initiated | Overweight | $26 | Apr 1, 2026 |
| William Blair | Initiated | Outperform | — | Mar 31, 2026 |
| Citigroup | Initiated | Buy | $23 | Mar 31, 2026 |
| Piper Sandler | Initiated | Neutral | $16 | Mar 31, 2026 |
| Mizuho | Initiated | Outperform | $21 | Mar 31, 2026 |
| Wells Fargo | Initiated | Overweight | $26 | Mar 31, 2026 |
| Morgan Stanley | Initiated | Overweight | $19 | Mar 31, 2026 |
| Evercore ISI Group | Initiated | Outperform | $20 | Mar 31, 2026 |
| B of A Securities | Initiated | Buy | $27 | Mar 31, 2026 |
| BTIG | Initiated | Buy | $25 | Mar 31, 2026 |
16 filings from 10 insiders · 0 buy / 0 sell over 6m
Officers and directors of MMED, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| SPOONER CHADChief Financial Officer | Grant | 116.6k | — | — | Jul 1, 2026 |
| WILLS COURTNEY NELSONGeneral Counsel | Grant | 82.8k | — | — | Jul 1, 2026 |
| DIANATY ALIOfficer | Grant | 131.3k | — | — | Jul 1, 2026 |
| CHANDRASENA GILLIANOfficer | Grant | 44.2k | — | — | Jul 1, 2026 |
| GYURCI JOHNOfficer | Grant | 24.2k | — | — | Jul 1, 2026 |
| DALLARA QUEChief Executive Officer | Grant | 297.6k | — | — | Jul 1, 2026 |
| SPOONER CHADChief Financial Officer | Grant | 269.4k | — | — | Mar 11, 2026 |
| WILLS COURTNEY NELSONGeneral Counsel | Grant | 55.1k | — | — | Mar 11, 2026 |
| DIANATY ALIChief Technology Officer | Grant | 191.3k | — | — | Mar 11, 2026 |
| CHANDRASENA GILLIANOfficer | Grant | 129.8k | — | — | Mar 11, 2026 |
| GYURCI JOHNOfficer | Grant | 15.3k | — | — | Mar 11, 2026 |
| DALLARA QUEChief Executive Officer | Grant | 621.6k | — | — | Mar 11, 2026 |
| EISENBERG GLENN ADirector | Grant | 13.9k | — | — | Mar 9, 2026 |
| LOFTON KEVIN EDirector | Grant | 27.8k | — | — | Mar 9, 2026 |
| WICKS TIMOTHY ADirector | Grant | 13.9k | — | — | Mar 9, 2026 |
| GROSSMAN DONALD KEITHDirector | Grant | 13.9k | — | — | Mar 9, 2026 |
No analyst notes on MMED yet.
Analyst Ratings
12 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 1 | 10 | 1 | 1 | 0 | Buy2.15 |
| 1 mo ago | 1 | 10 | 1 | 0 | 1 | Buy2.23 |
| 2 mo ago | 1 | 10 | 1 | 0 | 0 | Buy2.00 |
| 3 mo ago | 1 | 10 | 1 | 0 | 0 | Buy2.00 |